Release Date: December 23, 2025
Expiration Date: December 23, 2026
Activity Overview
Sickle cell disease (SCD) has entered a transformative era marked by significant progress in disease-modifying therapy (DMT) and curative strategies. This educational program brings together leading SCD experts to explore the latest evidence, real-world insights, and clinical considerations shaping modern SCD management. Drawing on evolving data and extensive experience caring for individuals with SCD, faculty will discuss therapies that are altering the natural history of the disease and expanding possibilities for long-term health.
Participants will hear experts break down clinical trial data, compare mechanisms of DMT, and provide practical commentary on integrating these options into everyday practice. The program will also highlight advances in curative approaches—including hematopoietic stem cell transplantation and gene-based therapies—emphasizing patient selection, safety considerations, evolving protocols, and the real-world challenges of implementation and access. This program aims to equip clinicians with the knowledge and expert perspective needed to navigate current options, evaluate emerging therapies, and support patients in making informed decisions about transformative and curative care pathways in SCD.
Target Audience
This educational activity is primarily directed toward hematologists, NPs, and PAs. Other clinicians involved in the care of SCD will also be invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
Assess clinical trial data for therapies for SCD
Integrate appropriate therapeutic approaches into individualized management plans for patients with SCD
Matthew Heeney, MD
Associate Chief, Hematology
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Boston, MA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Agios, Beam Therapeutics, Blueprint Medicines, Novartis, Novo Nordisk, Octapharma, Omeros, Pfizer, Sanofi; Grant/Research Funding: Agios, Beam Therapeutics, Novartis
Biree Andemariam, MD
Professor of Medicine
Director, New England Sickle Cell Institute
Director, Connecticut Bleeding Disorders Center
University of Connecticut Health
Farmington, CT
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Afimmune, Agios, Beam Therapeutics, bluebird bio, Bristol Myers Squibb, Chiesi, Editas, Fulcrum, Hemanext, Novo Nordisk, Octapharma, Pfizer, Roche, Sanofi, Vertex; Grant/Research Funding: Afimmune, Agios, Hemanext, Novo Nordisk, Pfizer
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.